Role of estrogens and progesterone in the etiology and prevention of endometrial cancer

Review

R. D. Gambrell, Carol Bagnell, R. B. Greenblatt

Research output: Contribution to journalReview article

83 Citations (Scopus)

Abstract

Our present knowledge of the role of sex steroids in the development as well as the prevention of endometrial cancer is reviewed. Factors which increase the exposure of the uterus to unopposed estrogens, either exogenous or endogenous, are associated with increased risk of endometrial adenocarcinoma. However, there is increasing evidence that progestogens can reverse endometrial hyperplasia and protect against the development of endometrial cancer. The mechanisms to explain the antiestrogenic effects of progestogens include changes in enzyme activity and steroid receptors in endometrial tissue. Postmenopausal women treated with combined estrogen and progestogen have the lowest incidence of endometrial carcinoma. Oral contraceptives containing both estrogen and progestogen in each tablet are protective against adenocarcinoma of the endometrium, while the sequential oral contraceptive pills afforded less protection. The risks and benefits of these hormone therapies are discussed in relation to the etiology and prevention of endometrial cancer.

Original languageEnglish (US)
Pages (from-to)696-707
Number of pages12
JournalAmerican Journal of Obstetrics and Gynecology
Volume146
Issue number6
DOIs
StatePublished - Jan 1 1983
Externally publishedYes

Fingerprint

Progestins
Endometrial Neoplasms
Progesterone
Estrogens
Contraceptives, Oral, Sequential
Adenocarcinoma
Endometrial Hyperplasia
Steroid Receptors
Oral Contraceptives
Endometrium
Tablets
Uterus
Steroids
Hormones
Incidence
Enzymes
Therapeutics

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this

@article{c77d1fa7b8014570a43248f06602958d,
title = "Role of estrogens and progesterone in the etiology and prevention of endometrial cancer: Review",
abstract = "Our present knowledge of the role of sex steroids in the development as well as the prevention of endometrial cancer is reviewed. Factors which increase the exposure of the uterus to unopposed estrogens, either exogenous or endogenous, are associated with increased risk of endometrial adenocarcinoma. However, there is increasing evidence that progestogens can reverse endometrial hyperplasia and protect against the development of endometrial cancer. The mechanisms to explain the antiestrogenic effects of progestogens include changes in enzyme activity and steroid receptors in endometrial tissue. Postmenopausal women treated with combined estrogen and progestogen have the lowest incidence of endometrial carcinoma. Oral contraceptives containing both estrogen and progestogen in each tablet are protective against adenocarcinoma of the endometrium, while the sequential oral contraceptive pills afforded less protection. The risks and benefits of these hormone therapies are discussed in relation to the etiology and prevention of endometrial cancer.",
author = "Gambrell, {R. D.} and Carol Bagnell and Greenblatt, {R. B.}",
year = "1983",
month = "1",
day = "1",
doi = "10.1016/0002-9378(83)91014-1",
language = "English (US)",
volume = "146",
pages = "696--707",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "6",

}

Role of estrogens and progesterone in the etiology and prevention of endometrial cancer : Review. / Gambrell, R. D.; Bagnell, Carol; Greenblatt, R. B.

In: American Journal of Obstetrics and Gynecology, Vol. 146, No. 6, 01.01.1983, p. 696-707.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Role of estrogens and progesterone in the etiology and prevention of endometrial cancer

T2 - Review

AU - Gambrell, R. D.

AU - Bagnell, Carol

AU - Greenblatt, R. B.

PY - 1983/1/1

Y1 - 1983/1/1

N2 - Our present knowledge of the role of sex steroids in the development as well as the prevention of endometrial cancer is reviewed. Factors which increase the exposure of the uterus to unopposed estrogens, either exogenous or endogenous, are associated with increased risk of endometrial adenocarcinoma. However, there is increasing evidence that progestogens can reverse endometrial hyperplasia and protect against the development of endometrial cancer. The mechanisms to explain the antiestrogenic effects of progestogens include changes in enzyme activity and steroid receptors in endometrial tissue. Postmenopausal women treated with combined estrogen and progestogen have the lowest incidence of endometrial carcinoma. Oral contraceptives containing both estrogen and progestogen in each tablet are protective against adenocarcinoma of the endometrium, while the sequential oral contraceptive pills afforded less protection. The risks and benefits of these hormone therapies are discussed in relation to the etiology and prevention of endometrial cancer.

AB - Our present knowledge of the role of sex steroids in the development as well as the prevention of endometrial cancer is reviewed. Factors which increase the exposure of the uterus to unopposed estrogens, either exogenous or endogenous, are associated with increased risk of endometrial adenocarcinoma. However, there is increasing evidence that progestogens can reverse endometrial hyperplasia and protect against the development of endometrial cancer. The mechanisms to explain the antiestrogenic effects of progestogens include changes in enzyme activity and steroid receptors in endometrial tissue. Postmenopausal women treated with combined estrogen and progestogen have the lowest incidence of endometrial carcinoma. Oral contraceptives containing both estrogen and progestogen in each tablet are protective against adenocarcinoma of the endometrium, while the sequential oral contraceptive pills afforded less protection. The risks and benefits of these hormone therapies are discussed in relation to the etiology and prevention of endometrial cancer.

UR - http://www.scopus.com/inward/record.url?scp=0020541155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020541155&partnerID=8YFLogxK

U2 - 10.1016/0002-9378(83)91014-1

DO - 10.1016/0002-9378(83)91014-1

M3 - Review article

VL - 146

SP - 696

EP - 707

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 6

ER -